Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220309 · ClinicalTrials.gov registry record
Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 167
- Enrollment target
NCT02220309: Completed study, sponsored by Stanford University.
NCT02220309 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 167 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02220309 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 167 participants
- Enrollment target
Study Summary
This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning. This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments. We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).
Interventions
- DRUG Pramipexole Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2013-08-11 |
| Est. Completion | 2025-04-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220309
The ClinicalTrials.gov registry entry for NCT02220309 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramipexole Oral Tablet is the first listed.
NCT02220309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02220309 about?
NCT02220309 is a clinical study titled "Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)". This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning. This study has recently added an additional treatment com...
What is the current status of trial NCT02220309?
This trial is currently completed. The enrollment target is 167 participants. The study started on 2013-08-11. Estimated completion is 2025-04-02.
What interventions are being tested in trial NCT02220309?
The interventions under investigation include: Pramipexole Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT02220309?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.